FDA convenes advisory panel to evaluate safety of popular wellness peptides
The Food and Drug Administration began a two-day meeting to review seven unapproved peptides promoted for muscle growth and injury recovery, amid disagreement between career scientists and industry-linked advisers.
Health advisers gathered Thursday for a two-day FDA meeting to assess more than half a dozen peptides that have become a growing wellness trend despite limited evidence of safety or efficacy. The review, backed by Health Secretary Robert F. Kennedy Jr., includes substances such as BPC-157 and TB-500, which are marketed online for muscle building, injury recovery and anti-aging benefits.
Career scientists at the agency have warned that data on the compounds are insufficient, citing concerns about contamination, allergic reactions and the lack of human studies. In a pre-meeting scientific review, FDA staff recommended against allowing the peptides to be compounded by pharmacies.
The advisory panel, composed of 20 members, features at least seven doctors or pharmacists with financial ties to the peptide industry, alongside newly added academics without such connections. The panel will vote on whether the seven peptides should be added to a list of substances deemed safe for compounding, though the votes are non-binding.
Public comments exceeding 1,900 submissions, including testimonies from physicians and patients, will also be considered. The American Academy of Peptide Medicine, representing doctors and wellness-clinic operators, argued that regulated pharmacy access would protect consumers from the “gray market.”
After the meeting, the FDA will review the advisory votes, discussion transcripts and public input before deciding on any policy changes. Analysts suggest the agency may issue a temporary reassurance to pharmacies rather than formally classifying the peptides as safe for compounding, a process that could take months or years.
"This is really alarming," said Rita Jew, president of the Institute for Safe Medication Practices.
"We’re still going through this process, but I think it’s more than likely that the process will end up at the result that Secretary Kennedy wants," said attorney Nathan Beaver.